Vimarsana
Biggest News Aggregation in the World

Page 23 - Dave Fredrickson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dave Fredrickson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dave Fredrickson Today - Breaking & Trending Today

FDA Approves Lynparza as Adjuvant Treatment in Early-Stage, BRCA1/2-Mutated Breast Cancer - Vimarsana News

FDA Approves Lynparza as Adjuvant Treatment in Early-Stage, BRCA1/2-Mutated Breast Cancer

Updated data from the pivotal OlympiA trial that led the drug's approval shows AstraZeneca and Merck's PARP inhibitor improves survival compared to placebo.

AstraZeneca to offer innovative oncology medicines to UAE, says top official - Vimarsana News

AstraZeneca to offer innovative oncology medicines to UAE, says top official

The British-Swedish pharma and biotechnology giant is “optimistic” about rapidly providing them

Patients to receive new cancer drugs faster under Brexit rules shake-up - Vimarsana News

Patients to receive new cancer drugs faster under Brexit rules shake-up

Seven medicines already approved as changes cut as much as a month off approval times

AstraZeneca: New Data In Liver, Biliary Tract, Prostate Cancer Treatment With Imfinzi And Lynparza - Vimarsana News

AstraZeneca: New Data In Liver, Biliary Tract, Prostate Cancer Treatment With Imfinzi And Lynparza

LONDON (dpa-AFX) - AstraZeneca (AZN.L, AZN) announced Thursday new data in liver, biliary tract and prostate cancer treatment with practice-changing Imfinzi and Lynparza.The company noted that

AstraZeneca aims to redefine liver, biliary tract and prostate cancer treatment with practice-changing Imfinzi and Lynparza data - Vimarsana News

AstraZeneca aims to redefine liver, biliary tract and prostate cancer treatment with practice-changing Imfinzi and Lynparza data

AstraZeneca will present new data in liver, biliary tract and prostate cancers illustrating its ambition to revolutionise cancer care at the 2022